Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

To compare combinations of varenicline plus the nicotine or placebo patch vs combinations used for either 12 weeks (standard duration) or 24 weeks (extended duration).

Why It Was Studied

Smoking cessation medications are routinely used in health care.

Who Took Part

The study group was 5836 adults.

PubMed indexes the participants as middle-aged adults, both men and women.

Of the 5836 adults asked to participate in the study, 1251 who smoked 5 cigarettes/d or more were randomized.

All participants received cessation counseling and were randomized to 1 of 4 medication groups: varenicline monotherapy for 12 weeks (n = 315), varenicline plus nicotine patch for 12 weeks (n = 314), varenicline monotherapy for 24 weeks (n = 311), or varenicline plus nicotine patch for 24 weeks (n = 311).

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The adults were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Neither the adults nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

The methods mention a period of 12 weeks.

Double-blind, 2 × 2 factorial randomized clinical trial conducted from November 11, 2017, to July 9, 2020, at 1 research clinic in Madison, Wisconsin, and at 1 clinic in Milwaukee, Wisconsin.

What Was Measured

The subject headings attached to it are Carbon Monoxide, Combined Modality Therapy, Confidence Intervals, Nausea, Nicotinic Agonists, Odds Ratio and Self Report.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 5836 adults over 12 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (JAMA), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.